Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...
USA: A first-in-class triple hormone receptor agonist, retatrutide, has demonstrated striking reductions in body weight along ...
Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...
Medindia on MSN
Botox for the First Time? Read This Before You Try It
Starting Botox? Learn what wrinkle relaxers do, how long results last, and why safety and proper technique matter.
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
News Quiz for Dec. 13, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback